Skip to main content

Latest SEC Filings — Page 189

Page 189 · 30 filings scored 7+ · newest 7:42 AM ET · How scores work

Thu, Aug 1330 filings
7PYXSPyxis Oncology, Inc.Pyxis Oncology Reports Q2 2026 Results, Extends Cash Runway into Q2 2027Form 8-K · Current report● Neutral7INKTMiNK Therapeutics, Inc.MiNK Reports Narrower Q2 Loss and First Randomized Phase 2 Data for agenT-797Form 8-K · Current report▲ Positive9KPTIKaryopharm Therapeutics Inc.Karyopharm Q2 Loss Widens to $67M; Cash Runs Out in SeptemberForm 10-Q · Periodic report▼ NegativePro8CREXCreative Realities, Inc.Record Q2 Revenue and a Major Grocery Chain Win for Creative RealitiesForm 8-K · Current report▲ PositivePro8MSGSMadison Square Garden Sports Corp.MSG Sports Q4 Revenue Jumps 37% on Knicks Championship; Rangers Spin-off Set for OctoberForm 8-K · Current report▲ PositivePro8ARCOArcos Dorados Holdings Inc.Arcos Dorados Q2 2026: Record Revenue, Net Income Doubles to $45MForm 6-K · Current report▲ PositivePro8KPTIKaryopharm Therapeutics Inc.Karyopharm Q2 Loss Widens to $67M; Cash Runway Only Into SeptemberForm 8-K · Current report▼ NegativePro8LUNRIntuitive Machines, Inc.Intuitive Machines Q2 Revenue Soars to $206M, Backlog Hits $1.8BForm 8-K · Current report▲ PositivePro8INDPIndaptus Therapeutics, Inc.Indaptus Halts Decoy20, Pivots to Strategic Alternatives with $11.6M CashForm 10-Q · Periodic report▼ NegativePro8CABACabaletta Bio, Inc.Cabaletta Bio Q2 2026: $51M Net Loss, Going Concern Warning Despite $225M CashForm 10-Q · Periodic report▼ NegativePro7CABACabaletta Bio, Inc.Cabaletta Bio Reports Q2 2026 Results, Cash Runway to Mid-2027, and Key Clinical MilestonesForm 8-K · Current report● Neutral7CRMDCorMedix Inc.CorMedix Q2 Revenue Jumps 157% to $101.9M, Raises Full-Year EBITDA GuidanceForm 8-K · Current report▲ Positive7ARCOArcos Dorados Holdings Inc.Arcos Dorados H1 2026 Net Income More Than Doubles to $81M; Redeems Remaining 2029 NotesForm 6-K · Current report▲ Positive7NGENNervGen Pharma Corp.NervGen Q2 Loss Widens on Warrant Charge; Phase 3 RESTORE Screening Set for SeptemberForm 6-K · Current report● Neutral8FBYDFalcon's Beyond Global, Inc.Falcon's Beyond Q2 10-Q: Revenue Doubles to $5.6M, But Going Concern Doubt PersistsForm 10-Q · Periodic report▼ NegativePro8GRCEGrace Therapeutics, Inc.Grace Therapeutics Takes $13.5M Impairment on Deprioritized Pipeline, Extends Cash Runway to 2028Form 10-Q · Periodic report▼ NegativePro8AFCGAdvanced Flower Capital Inc.AFCG Q2: Net Investment Income Rises, But Justice Cannabis Default LoomsForm 10-Q · Periodic report▼ NegativePro7ABEOABEONA THERAPEUTICS INC.Abeona Q2 2026: ZEVASKYN Revenue Grows 31% to $11.4M, Cash Runway ExtendedForm 10-Q · Periodic report● Neutral8YSWYYesway, Inc.Yesway Q2: Adjusted EBITDA up 35%, guidance raised to $235-$245MForm 8-K · Current report▲ PositivePro7COLLCollegium Pharmaceutical, Inc.Collegium Launches $50M Accelerated Share Repurchase at $25.70Form 8-K · Current report▲ Positive8FBYDFalcon's Beyond Global, Inc.Falcon's Beyond Q2 Revenue Doubles to $5.6M, But Going Concern Warning LoomsForm 8-K · Current report▼ NegativePro7INDPIndaptus Therapeutics, Inc.Indaptus Posts $1.8M Q2 Loss and Halts Decoy20 ProgramForm 8-K · Current report▼ Negative7ABEOAbeona Therapeutics Inc.Abeona Q2 Revenue Jumps 31% to $11.4M; ZEVASKYN Launch Gains TractionForm 8-K · Current report▲ Positive8COCPCocrystal Pharma, Inc.Cocrystal Pharma Q2 10-Q: Going Concern Persists Despite $5M OPKO PlacementForm 10-Q · Periodic report▼ NegativePro7RMTIRockwell Medical, Inc.Rockwell Medical Sets 2029 Targets: $100M+ Sales, 30% Gross Margin, No New Fundraising NeededForm 8-K · Current report▲ Positive8EVTLVertical Aerospace Ltd.Vertical Aerospace Reports H1 2026 Results, Flags Going Concern and Cash Runway to Q3 2027Form 6-K · Current report▼ NegativePro7ADIGADI Global Distribution Inc.ADI Posts Record Q2 Revenue of $1.29B, Initiates Standalone 2026 OutlookForm 8-K · Current report▲ Positive8CLRBCellectar Biosciences, Inc.Cellectar Advances Iopofosine Toward Mid-2027 NDA, Reports Q2 Loss and $34M CashForm 8-K · Current report▲ PositivePro7SSYSStratasys Ltd.Stratasys Q2 EPS Beats, But Cash Flow Guidance Turns Negative for 2026Form 6-K · Current report● Neutral7EUenCore Energy Corp.Wider Q2 Loss, Lower Uranium Extraction, and Workforce Reduction Reported by enCore EnergyForm 8-K · Current report▼ Negative
How Wiseek picks and scores these

How Wiseek curates this list

Every filing on this page is sourced directly from SEC EDGAR, the U.S. Securities and Exchange Commission's public filings system. Wiseek processes 8-K, 10-K, 10-Q, Form 4, Form 144, DEF 14A, Schedule 13D/A and related disclosures filed by U.S.-listed companies. The original filing is always linked from each article so readers can verify the source document directly.

How filings get scored

Each filing runs through Wiseek's importance scorer, which weights filing type, deal magnitude, insider participation, material-event flags (going-concern, restatements, executive transitions, M&A) and historical market-reaction patterns. Filings scoring below 7 on the 1–10 scale are filtered out at the database query so this list stays focused on market-moving disclosures. See our methodology for the full rubric.

Editorial standards

Wiseek does not edit the underlying SEC filing. Plain-English summaries and key-event extractions are generated from the verified source text and clearly attributed as AI-generated. Wiseek does not provide investment advice — see our editorial policy for full standards on accuracy, source disclosure, and corrections.

Track by company

Follow all SEC filings for a specific company by visiting its ticker page: AAPL, MSFT, NVDA, TSLA, AMZN, GOOGL, META, JPM, V, UNH, XOM, AVGO, LLY, MA, COST, JNJ, PG, HD, ABBV, MRK, KO, NFLX, AMD, WMT, CVX, BAC — or browse all covered tickers.